Clinical trial
Intravenous Recombinant Human Prourokinase for Extended-Window Acute Ischemic Stroke Selected by NCCT-Based Artificial Intelligence: A Randomized Controlled Trial
NCT07901842 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 3, 826 participants (estimated). Lead sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine; China. Primary measure: Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 Days.
How it compares
263 similar trials: same condition (Ischemic Stroke) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravenous Recombinant Human Prourokinase for Extended-Window Acute Ischemic Stroke Selected by NCCT-Based Artificial Intelligence: A Randomized Controlled Trial
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- June 1, 2030
- Enrollment
- 826 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: acute ischemic stroke
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Recombinant Human Prourokinase Group | Experimental | Recombinant Human Prourokinase for Injection (rhPro-UK) |
Show registry wordingParticipants will receive intravenous recombinant human prourokinase (rhPro-UK), 35 mg, in addition to guideline-recommended standard stroke care. | ||
| Matching Placebo Group | Placebo comparator | Matching Placebo for Recombinant Human Prourokinase |
Show registry wordingParticipants will receive matching intravenous placebo in addition to the same guideline-recommended standard stroke care. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 Days | 90 ± 7 days after randomization |
Show registry wordingThe proportion of participants achieving a modified Rankin Scale (mRS) score of 0 or 1. The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional outcomes. | |
Lead sponsor's other trials
Second Affiliated Hospital, Zhejiang University, School of Medicine, most recent start first.
+1,141 more trials
Similar trials
Same condition (Ischemic Stroke) and phase, most recent start first.
+258 more trials See the condition page